The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib

Experimental Cell Research

Volumn 295, Issue 2, 2004, Pages 555-566

  Yu, Chunrong ^a   Rahmani, Mohamed ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Bortezomib; JNK; MAPK; ROS

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIOXIDANT; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROTECTION; CELL STRAIN U937; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INACTIVATION; FEEDBACK SYSTEM; GENE CONSTRUCT; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELOMONOCYTIC LEUKEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 1842861723     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.02.001     Document Type: Article

References (39)

1. Almond J.B., Cohen G.M. The proteasome: a novel target for cancer chemotherapy. Leukemia. 16:2002;433-443.
2. Ciechanover A., Orian A., Schwartz A.L. The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications. J. Cell. Biochem. 77:2000;40-51.
3. Yang Y., Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J. 17:2003;790-799.
4. Adams J. Proteasome inhibitors as new anticancer drugs. Curr. Opin. Oncol. 14:2002;628-634.
5. Schenkein D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma. 3:2002;49-55.
6. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazaruz D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622.
7. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. 6:2002;493-500.
8. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of Bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2003;2609-2617.
9. Lin Z.P., Boller Y.C., Amer S.M., Russell R.L., Pacelli K.A., Patierno S.R., Kennedy K.A. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. Cancer Res. 58:1998;3059-3065.
10. Fukazawa T., Fujiwara T., Uno F., Teraishi F., Kadowaki Y., Itoshima T., Takata Y., Kagawa S., Roth J.A., Tschopp J., Tanaka N. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene. 20:2001;5225-5231.
11. Meriin A.B., Gabai V.L., Yaglom J., Shifrin V.I., Sherman M.Y. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J. Biol. Chem. 273:1998;6373-6379.
12. Chang F., Steelman L.S., Shelton J.G., Lee J.T., Navolanic P.M., Blalock W.L., Franklin R., McCubrey J.A. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int. J. Oncol. 22:2003;469-480.
13. Cobb M.H. MAP kinase pathways. Prog. Biophys. Mol. Biol. 71:1999;479-500.
14. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:1997;90-94. (Washington DC).
15. Hideshima T., Mitsiades C., Akiyama M., Hayashi T., Chauhan D., Richardson P., Schlossman R., Podar K., Munshi N.C., Mitsiades N., Anderson K.C. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 101:2003;1530-1534.
16. Orlowski R.Z., Small G.W., Shi Y.Y. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J. Biol. Chem. 277:2002;27864-27871.
17. Ling Y.H., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. 278:2003;33714-33723.
18. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192:2002;1-15.
19. Jia W., Yu C., Rahmani M., Krystal G., Sausville E.A., Dent P., Grant S. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood. 102:2003;1824-1832.
20. Yu C., Wang S., Dent P., Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Mol. Pharmacol. 60:2003;143-154.
21. + cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biother. 2:2003;544-551.
22. Yu C., Rahmani M., Almenara J., Subler M., Krystal G., Conrad D., Varticovski L., Dent P., Grant S. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63:2003;2118-2126.
23. Fan M., Goodwin M., Vu T., Brantley-Finley C., Gaarde W.A., Chambers T.C. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J. Biol. Chem. 275:2000;29980-29985.
24. Scheid M.P., Schubert K.M., Duronio V. Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J. Biol. Chem. 274:1999;31108-31113.
25. Allan L.A., Morrice N., Brady S., Magee G., Pathak S., Clarke P.R. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat. Cell Biol. 5:2003;647-654.
26. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., Bar-Sagi D., Jones S.N., Flavell R.A., Davis R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 288:2000;870-874.
27. Yu C., Rahmani M., Conrad D., Subler M., Dent P., Grant S. The proteasome inhibitor Bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 102:2003;3765-3774.
28. Yamamoto K., Ichijo H., Korsmeyer S.J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 19:1999;8469-8478.
29. Inoshita S., Takeda K., Hatai T., Terada Y., Sano M., Hata J., Umezawa A., Ichijo H. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J. Biol. Chem. 277:2002;43730-43734.
30. Jarvis W.D., Auer K.L., Spector M., Kunos G., Grant S., Hylemon P., Mikkelsen R., Dent P. Positive and negative regulation of JNK1 by protein kinase C and p42 (MAP kinase) in adult rat hepatocytes. FEBS Lett. 412:1997;9-14.
31. Reffas S., Schlegel W. Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. Biochemistry. 352:2000;701-708.
32. Hirsch D.D., Stork P.J. Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways in vivo. J. Biol. Chem. 272:1997;4568-4575.
33. Matsuzawa A., Ichijo H. Molecular mechanisms of the decision between life and death: regulation of apoptosis by apoptosis signal-regulating kinase 1. J. Biochem. (Tokyo). 130:2001;1-8.
34. Sanchez I., Hughes R.T., Mayer B.J., Yee K., Woodgett J.R., Avruch J., Kyriakis J.M., Zon L.I. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature. 372:1994;794-798.
35. Avdi N.J., Malcolm K.C., Nick J.A., Worthen G.S. A role for protein phosphatase-2A in p38 mitogen-activated protein kinase-mediated regulation of the c-Jun NH(2)-terminal kinase pathway in human neutrophils. J. Biol. Chem. 277:2002;40687-40696.
36. Todd J.L., Rigas J.D., Rafty L.A., Denu J.M. Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). Oncogene. 21:2002;2573-2583.
37. Guyton K.Z., Liu Y., Gorospe M., Xu Q., Holbrook N.J. Activation of mitogen-activated protein kinase by H2O2. Role in cell survival following oxidant injury. J. Biol. Chem. 271:1996;4138-4142.
38. Luo Y., Umegaki H., Wang X., Abe R., Roth G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 273:1998;3756-3764.
39. Nordberg J., Arner E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biol. Med. 31:2001;1287-1312.